Cargando…
Dexamethasone and Nutraceutical Therapy Can Reduce the Myalgia Due to COVID-19 – a Systemic Review of the Active Substances that Can Reduce the Expression of Interlukin-6
BACKGROUND: Myalgia reflects generalized inflammation and cytokine response and can be the onset symptom of 36% of patients with COVID-19. Interleukin-6 (IL-6) and tumor necrosis factor-α (TNF- α) levels in plasma and upper respiratory secretions directly correlate with the magnitude of viral replic...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Medical Sciences of Bosnia and Herzegovina
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976893/ https://www.ncbi.nlm.nih.gov/pubmed/35422571 http://dx.doi.org/10.5455/medarh.2022.76.66-71 |
_version_ | 1784680661226881024 |
---|---|
author | Ripani, Umberto Bisaccia, Michele Meccariello, Luigi |
author_facet | Ripani, Umberto Bisaccia, Michele Meccariello, Luigi |
author_sort | Ripani, Umberto |
collection | PubMed |
description | BACKGROUND: Myalgia reflects generalized inflammation and cytokine response and can be the onset symptom of 36% of patients with COVID-19. Interleukin-6 (IL-6) and tumor necrosis factor-α (TNF- α) levels in plasma and upper respiratory secretions directly correlate with the magnitude of viral replication, fever, and respiratory and systemic symptoms, including musculoskeletal clinical manifestations. OBJECTIVE: The aim of our work is to report literature scientific investigation clinical protocol to reduce the immunomodulation and inflammatory response nutraceutical therapy associated with dexamethasone and how can reduce the expression of Interlukina-6(IL-6) and myalgia due to COVID-19. METHODS: We searched in Pubmed and Cochrane the nautriceutical drugs to treat the immune modulation of organism to COVID-19. We put these keywords: immune inflammation, desease descriptions, epidemiology COVID-19; immunomodulations; IL-6; Rheumatic Symptoms; Joint; Musculoskeletal Disorders; dexamethasone; Polydatin; Zinc; Melatonin; N- Acetyl Cysteine; Colostrum; L- Glutamine; Vitamin D3. RESULTS: We found 61 papers. All the authors analyze them. After the Analyze we suggest the use of response nutraceutical therapy associated with dexamethasone can reduce the expression of Interlukina-6(IL-6) and myalgia due to COVID-19. CONCLUSION: According the scientific literature nutraceutical therapy associated with dexamethasone can reduce the expression of Interlukina-6(IL-6) and myalgia due to COVID-19. |
format | Online Article Text |
id | pubmed-8976893 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Academy of Medical Sciences of Bosnia and Herzegovina |
record_format | MEDLINE/PubMed |
spelling | pubmed-89768932022-04-13 Dexamethasone and Nutraceutical Therapy Can Reduce the Myalgia Due to COVID-19 – a Systemic Review of the Active Substances that Can Reduce the Expression of Interlukin-6 Ripani, Umberto Bisaccia, Michele Meccariello, Luigi Med Arch Review BACKGROUND: Myalgia reflects generalized inflammation and cytokine response and can be the onset symptom of 36% of patients with COVID-19. Interleukin-6 (IL-6) and tumor necrosis factor-α (TNF- α) levels in plasma and upper respiratory secretions directly correlate with the magnitude of viral replication, fever, and respiratory and systemic symptoms, including musculoskeletal clinical manifestations. OBJECTIVE: The aim of our work is to report literature scientific investigation clinical protocol to reduce the immunomodulation and inflammatory response nutraceutical therapy associated with dexamethasone and how can reduce the expression of Interlukina-6(IL-6) and myalgia due to COVID-19. METHODS: We searched in Pubmed and Cochrane the nautriceutical drugs to treat the immune modulation of organism to COVID-19. We put these keywords: immune inflammation, desease descriptions, epidemiology COVID-19; immunomodulations; IL-6; Rheumatic Symptoms; Joint; Musculoskeletal Disorders; dexamethasone; Polydatin; Zinc; Melatonin; N- Acetyl Cysteine; Colostrum; L- Glutamine; Vitamin D3. RESULTS: We found 61 papers. All the authors analyze them. After the Analyze we suggest the use of response nutraceutical therapy associated with dexamethasone can reduce the expression of Interlukina-6(IL-6) and myalgia due to COVID-19. CONCLUSION: According the scientific literature nutraceutical therapy associated with dexamethasone can reduce the expression of Interlukina-6(IL-6) and myalgia due to COVID-19. Academy of Medical Sciences of Bosnia and Herzegovina 2022-02 /pmc/articles/PMC8976893/ /pubmed/35422571 http://dx.doi.org/10.5455/medarh.2022.76.66-71 Text en © 2022 Umberto Ripani, Michele Bisaccia, Luigi Meccariello https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Ripani, Umberto Bisaccia, Michele Meccariello, Luigi Dexamethasone and Nutraceutical Therapy Can Reduce the Myalgia Due to COVID-19 – a Systemic Review of the Active Substances that Can Reduce the Expression of Interlukin-6 |
title | Dexamethasone and Nutraceutical Therapy Can Reduce the Myalgia Due to COVID-19 – a Systemic Review of the Active Substances that Can Reduce the Expression of Interlukin-6 |
title_full | Dexamethasone and Nutraceutical Therapy Can Reduce the Myalgia Due to COVID-19 – a Systemic Review of the Active Substances that Can Reduce the Expression of Interlukin-6 |
title_fullStr | Dexamethasone and Nutraceutical Therapy Can Reduce the Myalgia Due to COVID-19 – a Systemic Review of the Active Substances that Can Reduce the Expression of Interlukin-6 |
title_full_unstemmed | Dexamethasone and Nutraceutical Therapy Can Reduce the Myalgia Due to COVID-19 – a Systemic Review of the Active Substances that Can Reduce the Expression of Interlukin-6 |
title_short | Dexamethasone and Nutraceutical Therapy Can Reduce the Myalgia Due to COVID-19 – a Systemic Review of the Active Substances that Can Reduce the Expression of Interlukin-6 |
title_sort | dexamethasone and nutraceutical therapy can reduce the myalgia due to covid-19 – a systemic review of the active substances that can reduce the expression of interlukin-6 |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976893/ https://www.ncbi.nlm.nih.gov/pubmed/35422571 http://dx.doi.org/10.5455/medarh.2022.76.66-71 |
work_keys_str_mv | AT ripaniumberto dexamethasoneandnutraceuticaltherapycanreducethemyalgiaduetocovid19asystemicreviewoftheactivesubstancesthatcanreducetheexpressionofinterlukin6 AT bisacciamichele dexamethasoneandnutraceuticaltherapycanreducethemyalgiaduetocovid19asystemicreviewoftheactivesubstancesthatcanreducetheexpressionofinterlukin6 AT meccarielloluigi dexamethasoneandnutraceuticaltherapycanreducethemyalgiaduetocovid19asystemicreviewoftheactivesubstancesthatcanreducetheexpressionofinterlukin6 |